Please login to the form below

Not currently logged in
Email:
Password:

Imnovid

This page shows the latest Imnovid news and features for those working in and with pharma, biotech and healthcare.

NICE U-turn sees Celgene's Imnovid backed for multiple myeloma

NICE U-turn sees Celgene's Imnovid backed for multiple myeloma

NICE U-turn sees Celgene's Imnovid backed for multiple myeloma. New data and a discount swayed the cost-effectiveness body. ... The National Institute for Health and Care Excellence has backed Celgene's multiple myeloma pill Imnovid (pomalidomide) in

Latest news

  • Cancer Drugs Fund axes 16 treatments after overspending Cancer Drugs Fund axes 16 treatments after overspending

    Patients in Scotland will nevertheless still be able to receive both treatments and the All Wales Medicine Strategy Group (AWMSG) recently approved Imnovid for use on the NHS. ... Wim Souverjins, general manager at Celgene UK &Ireland, said: “ We are

  • Final NICE ‘no’ for Celgene’s Imnovid Final NICE ‘no’ for Celgene’s Imnovid

    Final NICE ‘ no’ for Celgene’ s Imnovid. England’ s pricing watchdog says multiple myeloma drug is just too expensive for the NHS. ... NICE has issued final draft guidance rejecting Celgene's next-generation multiple myeloma pill Imnovid

  • Celgene gets first-line myeloma approval for Revlimid Celgene gets first-line myeloma approval for Revlimid

    Celgene said recently that strong growth for Revlimid as well as its newer products, including Pomalyst/Imnovid (pomalidomide) for myeloma - which the company predicts will become a multibillion-dollar product - as

  • NICE issues fresh rejection for Celgene’s cancer drug Imnovid NICE issues fresh rejection for Celgene’s cancer drug Imnovid

    NICE issues fresh rejection for Celgene’ s cancer drug Imnovid. Drugpricing watchdog says the treatment is too costly for NHS use. ... NICE has issued final draft guidance that rejects the use of Celgene's next generation multiple myeloma pill Imnovid

  • Cancer drugs lead SMC recommendations Cancer drugs lead SMC recommendations

    The SMC, which rules on what drugs are available for NHS reimbursement, backed Roche's Gazyvaro (obinutuzumab), Eli Lilly's Alimta (pemetrexed) and Celgene's Imnovid (pomalidomide), in addition to several ... The recommendation for Alimta is regarding

More from news
Approximately 6 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics